Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials
Published version of a preprint
The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To provide an updated synthesis on effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) on weight, BMI, and waist circumference incorporating newer randomized controlled trials (RCTs), particularly in individuals with overweight or obesity. RESEARCH DESIGN AND METHODS: We systematically searched PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) for RCTs published from inception to 4 October 2024. The search was limited to RCTs evaluating the use of GLP-1 RAs for mean differences from baseline in weight, BMI, and waist circumference in adults with obesity or overweight with or without diabetes. Two independent reviewers performed the literature search and data extraction, resolving disagreements via consensus or third-reviewer consultation. RESULTS: Forty-seven RCTs were included, with a combined cohort of 23,244 patients. GLP-1 RAs demonstrated a mean weight reduction of −4.57 kg (95% CI −5.35 to −3.78), mean BMI reduction of −2.07 kg/m2 (95% CI −2.53 to −1.62), and mean waist circumference reduction of −4.55 cm (95% CI −5.72 to −3.38) compared with placebo. This effect was consistent across diabetes status, GLP-1 RA used, and route of administration. The greatest treatment benefit appeared to favor patients who were younger, female, without diabetes, with higher baseline weight and BMI but lower baseline HbA1c, and treated over a longer duration. Limitations include substantial statistical heterogeneity, in part due to broad inclusion criteria. However, this heterogeneity may improve generalizability by reflecting a wide range of study designs and patient populations. CONCLUSIONS: GLP-1 RAs demonstrated significant weight, BMI, and waist circumference reduction benefits in this meta-analysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent literature shows that GLP-1 receptor agonists are highly effective for weight loss and improving metabolic and cardiovascular health, often surpassing the results of lifestyle interventions alone, such as exercise and diet modification.”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
In the citing paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
In the citing paper
“GLP-1RAs, including liraglutide and semaglutide, can induce substantial weight loss (often 10–15% or more), improve cardiometabolic risk factors, including histological damage associated with metabolic dysfunction–associated steatohepatitis (MASH) (3), and reduce major adverse cardiovascular events in both diabetic and non-diabetic populations (1, 4–12).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
In the citing paper
“GLP-1RAs consistently demonstrate significant weight loss (mean reductions of 7–9 kg of body weight over a period of about a year) and improvements in BMI, waist circumference, blood pressure, and lipid profiles in both diabetic and non-diabetic populations (5–7, 10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
In the citing paper
“Current evidence strongly supports the efficacy of GLP-1 receptor agonists for inducing substantial weight loss, improving metabolic control, and reducing cardiovascular risk – often surpassing the short-term effects of exercise alone (4–10, 23).”
From GLP-1 agonists and exercise: the future of lifestyle prioritization (2025) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2_v1 · Cited by 8,090
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J., Bossuyt, P., Boutron, I., Hoffmann, T., mulrow, C., Shamseer, L., Tetzlaff, J., Akl, E., Brennan, S. E., et al. (2020) · doi:10.31222/osf.io/v7gm2 · Cited by 5,177
Hubert, H. B., Feinleib, M., McNamara, P. M., & Castelli, W. P. (1983) · Circulation · doi:10.1161/01.cir.67.5.968 · Cited by 4,241
Guh, D. P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C. L., & Anis, A. H. (2009) · BMC Public Health · doi:10.1186/1471-2458-9-88 · Cited by 3,855
Obesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology
Guyatt, G. H., Oxman, A. D., Schünemann, H. J., Tugwell, P., & Knottnerus, A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.011 · Cited by 3,094
Methley, A. M., Campbell, S., Chew-Graham, C., McNally, R., & Cheraghi-Sohi, S. (2014) · BMC Health Services Research · doi:10.1186/s12913-014-0579-0 · Cited by 2,706
Research works printed but not linked: 2
- World Health Organization, 2000, The Asia-Pacific Perspective: Redefining Obesity and Its Treatment.
- Higgins, 2023, Cochrane Handbook for Systematic Reviews of Interventions Version 6.4.
Cited by
Items 101–200 of 209
Temperley, H. C., Coalter, M., Creavin, B., Jordan, P., Hogan, A. E., O'Sullivan, J. N., O'Shea, D. B., McCormick, P. H., Harrold, E., & Kelly, M. E. (2026) · British journal of surgery · doi:10.1093/bjs/znag029 · Cited by 2
Gormsen, J., & Helgstrand, F. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.03.016 · Cited by 1
Bi, Z., Jiao, Z., Li, J., & Fang, Z. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-08016-x · Cited by 1
Papazova, E., Mitschke, S., Laue, C., & Schrezenmeir, J. (2026) · Nutrients · doi:10.3390/nu18081174 · Cited by 1
Singh, A., Horvit, A. M., Abramowitz, J. D., Abreu, M., Kaput, K. L., Neece, A., Ratti, G. A., Finklea, J. D., Jain, R., & Mirfakhraee, S. (2026) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2026.05.009 · Cited by 1
Plotkin, M., Ivkovic, M., Smith, I., Rathor, N., Chowdhury, R., Hodkinson, A., & Kushner, R. F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70911 · Cited by 2
Zickler, C. L., Alfonsi, S. P., Shalakthi, O. S., Alli, N. K., Acuña, A. J., Forlenza, E. M., Terhune, E. B., & Burnett, R. A. (2026) · Knee Surgery Sports Traumatology Arthroscopy · doi:10.1002/ksa.70473 · Cited by 1
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management
Rubino, D., Wharton, S., Knight, M. G., & Aroda, V. R. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2686467 · Cited by 1
Unravelling obesity: from leptin to glucagon-like peptide-1 receptor agonists
Idowu, T. O., & Chmurzyńska, A. (2026) · Journal of Applied Genetics · doi:10.1007/s13353-026-01084-5 · Cited by 1
Comparative Outcomes of GLP-1 Therapy vs. Bariatric Surgery in Patients with Cirrhosis
Aburumman, R., Alsakarneh, S., Madi, M., & Jafri, S. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08823-x · Cited by 1
Olumuyide, E. O., Ariel, K., & Aneni, E. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02143-x · Cited by 1
Bilal, A. R., Sajid, M., Arfin, S. M. W., Bilal, A. R., Gaba, H., Qureshi, S., Farooq, M. Z., Inam, M. H., Aminpoor, H., & Waqas, S. A. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02000-8 · Cited by 1
Risk of pancreatic cancer associated with GLP-1 receptor agonist therapy
Krishna, S., Dungan, K. M., Shah, R., Cruz‐Monserrate, Z., DelGiorno, K. E., Tan, M., & Hart, P. A. (2026) · npj gut and liver. · doi:10.1038/s44355-026-00069-9 · Cited by 1
Nadolsky, S., Kessel, S., Krumm, Z. A., & Tinsley, G. M. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100302 · Cited by 1
Ahmed, M. M., Nazari, R., Othman, Z. K., Musa, S. S., Okesanya, O. J., Adebayo, U. O., Branda, F., Elmi, A. H., & Prisno, D. E. L. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261472587 · Cited by 2
Brouer, I. C., Zani, A., Olbrich, H., Ludwig, R. J., & Thaçi, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1909537 · Cited by 1
Martins, A. L. S., de Lima, L. R., & de Souza, T. E. G. (2025) · Journal Archives of Health · doi:10.46919/archv6n3-006 · Cited by 1
Metabolic health and strategies for a Healthier SG
Khoo, J. J. C., Lim, R. L. C., Ng, L. P., Phoon, I. K. Y., Gani, L. U., Puar, T. H. K., How, C. H., & Loh, W. J. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-157 · Cited by 1
Huang, J. W. (2025) · Diabetes Care · doi:10.2337/dc25-0267 · Cited by 1
Weight loss injections for the obese and unemployed in the UK: is wellbeing the missing link?
Madan, V. (2025) · Discover Social Science and Health · doi:10.1007/s44155-025-00213-5
Potential Therapeutic Benefits of Glucagon-Like-Peptide-1 Agonists and Atrial Fibrillation
Zhang, H., Maksymiuk, V., Frishman, W. H., & Aronow, W. S. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001003
Lauerer, J., Kollmann, L., Koschker, A., Otto, M., & Seyfried, F. (2025) · Die Chirurgie · doi:10.1007/s00104-025-02384-y
Is Superior Weight Loss the Most Important Outcome in Bariatric Surgery?
Khorfan, R., & Ehlers, A. P. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.3597
Fatty Kidney Disease: Current Understanding in 2025
Aung, H. M., Wazeed, N., Wagle, A., Burke, K., & Jim, B. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001060
Interdisziplinäre Strategien zur Prävention und Therapie der MASLD
Roehlen, N., Laubner, K., Seufert, J., & Thimme, R. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2532-5919
Disu, F., Okoro, N. L., Mochu, A. W., Martey, A. R., Shittu, S. A., Green, J. T., & Azubike, W. C. (2025) · Cureus · doi:10.7759/cureus.94373
Basal insulin in the age of innovation: are diamonds still forever?
Koufakis, T., Patoulias, D., Popovic, D. S., & Tsimihodimos, V. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2580629
Brennan-Davies, A. H., & Lakey, S. (2025) · Cureus · doi:10.7759/cureus.97124 · Cited by 2
Pharmacologic management of diabetes in older adults
Sia, C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29025-1.00007-2
Self-citationLiechti, M., Menegon, M., Schurz, A. P., Vanroose, M., Clijsen, R., Malfliet, A., Faeh, D., Baur, H., Taeymans, J., & Lutz, N. (2025) · Archives of Physiotherapy · doi:10.33393/aop.2025.3590
Clyde, D., Healey, A. J., & Damaskos, D. (2025) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-025-04191-0
Pharmacologic glycemic management of type 2 diabetes
Mourelatou, N. G., & Rebelos, E. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00284-3
Khela, H. S., Kishan, A., Manriquez, A. H., Kirby, L., Chisango, Z. M., Carayannopoulos, N. L., Singh, M., Cottrill, E. J., Avedian, R. S., Kleck, C. J., et al. (2026) · Spine Open · doi:10.1097/bn9.0000000000000051
ADVERSE EFFECTS OF GLP-1 RECEPTOR AGONISTS: A COMPREHENSIVE APPROACH
Sapeda, N., Lusarczyk, W., Truszyńska-Zawisza, A., Gorczyca, K., Młocek, A., Romanowska, Z., & Białas, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4111
Kelepile, M., Kebotsamang, K., Mawi, M., Molebatsi, K., Molefe‐Baikai, O. J., Babayani, N. D., Grady, S. C., Mogaetsho, E., Moshomo, T., Kgotlaetsile, K., et al. (2026) · BMC Public Health · doi:10.1186/s12889-026-26247-1
Vafeidou, K., Koufakis, T., Stavropoulos, K., Zarfeiadou, M., Doumas, M. N., & Patoulias, D. (2026) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2026.2634086
Crossing the line: BMI category changes with tirzepatide
Kelsey, M. D., & Pagidipati, N. J. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101490
FROM LIFESTYLE INTERVENTIONS TO BARIATRIC SURGERY: AN OVERVIEW OF OBESITY TREATMENT MODALITIES
Jamroch, K., Marek, A., Garncarz, K., Dziki, K., Dybizbańska, W., Nowakowska, Z., Burzej, A., Kacalak, M., Komenda, M., & Szklarska-Komenda, J. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4420
Rosenbaum, D. L. (2026) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-026-01833-9 · Cited by 1
Chang, Y.-J., Fuh, C., Chang, J.-F., Chen, M., & Tsai, M. (2026) · Bone · doi:10.1016/j.bone.2026.117851
Markovic, E. S., Ward, H., Khanuja, K., & McLaren, R. A. (2026) · American Journal of Perinatology · doi:10.1055/a-2832-1764
Wada, Y., Toyoda, M., Kobayashi, K., Aoyama, T., Kanamori, A., & Takeuchi, Y. (2026) · Clinical and Experimental Nephrology · doi:10.1007/s10157-026-02845-6
Filatova, E. V., & Konopatkina, I. Y. (2026) · Восстановительные биотехнологии, профилактическая, цифровая и предиктивная медицина. · doi:10.17116/rbpdpm2026301144
Medenica, S., Prelević, V., Zanković, N., Maggio, V., & Rizzo, M. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2648248 · Cited by 1
Marassi, M., Pollis, R. M., & Fadini, G. P. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104714
Box, M. W., Puga, T. B., Poffenbarger, M., Liu, Y., & Riehl, J. T. (2026) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-026-04720-2
Khan, S., Khan, S. S., Mouazen, S. M., Ramadan, Z. M., Khan, S. S., Aldawood, Y. O., & Neto, M. G. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08588-3
Latt, T. S., Aye, T. T., Ko, K. O. H., Win, S. S., Chit, T. T., & Myint, K. N. S. (2026) · Cureus · doi:10.7759/cureus.106767
Endogenous Incretin Insufficiency in Obesity: Etiological Defect or Metabolic Maladaptation?Preprint
Andrade, L. J. D. O., de Oliveira, G. C. M., Bittencourt, A. M. V., Salles, O. J. D. M., & de Oliveira, L. M. (2026) · Research Square · doi:10.21203/rs.3.rs-9453154/v1
From Single-target to System Remodeling:Combination Therapeutic Strategies for Metabolic Diseases
Xie, Z., & Li, J. (2026) · 中国科学基金 · doi:10.3724/bnsfc-2025-0006
Rivera, N., Bradley, T., Cottrill, E. J., Ray, E. J., Zachem, T. J., Crowell, K., Goodwin, C. R., & Erickson, M. M. (2026) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000002064 · Cited by 1
Discovery of a new GLP-1 receptor agonist using DNA encoded-libraries and similarity search
Lee, J. H., Kim, D., Jeon, H., Park, S. B., Koh, B., Lim, B., Lee, K. A., Choi, K. J., Kim, S. S., Kwon, Y., et al. (2026) · Results in Chemistry · doi:10.1016/j.rechem.2026.103415 · Cited by 1
Navas, A., NOONE, J., Laney, N., SHETH, S. T., Tan, X., Liang, Y. M., Munoz, P., & Swift, C. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01875-3 · Cited by 1
Using GLP-1s to improve health: Fear of fat and “obesity” discourse
Prohaska, A., & Debus, C. (2026) · Fat Studies · doi:10.1080/21604851.2026.2674153
Zhu, L., Hongning, L. I., Zhang, Y., Tao, S., Rengna, Y., Luo, Y., Shen, Z., Li, H., Kong, X., & Ma, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1810786
Stier, C. K., Chiappetta, S., & Kermansaravi, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70890
Parekh, R. S., Inban, P., Thai, A., Agrawal, A., Kudaiarov, D., & Tariq, H. (2026) · Disease-a-Month · doi:10.1016/j.disamonth.2026.102150
Matsushita, T., Wada, Y., Saburi, M., Kobayashi, K., Tsukamoto, S., Kawanami, D., Suzuki, D., Tsuriya, D., Wakui, H., Kanasaki, K., et al. (2026) · Hypertension Research · doi:10.1038/s41440-026-02695-5
Mann, D. M., Thiel, C. L., Henning, N., Lawrence, K. S., & Stevens, E. R. (2026) · Journal of Public Health Management and Practice · doi:10.1097/phh.0000000000002387
McCann, C. J., Clement, N., Murray, A. D., Kearney, R., Madigan, S. M., Gee, C. W., Walmsley, P., Morrison, S. R., Chopra, S., & Hall, A. J. (2026) · British Journal of Sports Medicine · doi:10.1136/bjsports-2025-111225 · Cited by 1
Li, R., Zhao, X., Shen, J., Luo, B., Wang, Y., & Duan, Y. (2026) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2026.103548
Barrett, P., Brooks, C. P., McCluskey, S., & Brown, A. (2026) · Journal of Eating Disorders · doi:10.1186/s40337-026-01634-6 · Cited by 1
GLP-1 therapies for obesity: mechanisms, outcomes, and regulatory challenges
Emos, D. D. O., González, J. D. J. M., Diani, L. M., Pinhel, M. A. D. S., Watanabe, L. M., Leca, A. V., Brandao, C. F. C., Nonino, C. B., & Noronha, N. Y. (2026) · Academia Drug Development and Pharmacotherapy · doi:10.20935/acaddrug8360
Weight Loss Following Liraglutide Therapy in a Patient With Smith-Magenis Syndrome: A Case Report
Garg, D. K., & Wei, J. (2026) · Cureus · doi:10.7759/cureus.111313
Amaro, I., Paula, A. B., Coelho, A. S. E. D. C., Marto, C. M., Laranjo, M., Alarico, S., Rodrigues, D., Oliveiros, B., & Carrilho, E. (2026) · Medical Sciences · doi:10.3390/medsci14030336
Xu, H. H., Dominguez, E., Mroueh, V., Duncan, A., Bottegal, M. T., Kim, S., & Solari, M. G. (2026) · Journal of Reconstructive Microsurgery · doi:10.1055/a-2903-1493
Body Composition Considerations in Glucagon-Like Peptide-1 Receptor Agonists Treatment
Zydel, D., Sterczala, A. J., Young, M. T., Blakeley, N. L., Forman, D. E., & Herrle, S. R. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.07.002
Spiazzi, B. F., Zingano, C. P., Colpani, V., & Gerchman, F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113431 · Cited by 3
Abegaz, T. M., & Frietze, G. A. (2026) · Frontiers in Artificial Intelligence · doi:10.3389/frai.2026.1861563 · Cited by 2
Caimi, E., Ghetti, E. M., Giovagnoli, F., Vaccari, S., Ceglia, G., Cavallero, M. F., Comunian, R., Giuli, R. D., Veronesi, A., Klinger, F. M., et al. (2026) · Aesthetic Plastic Surgery · doi:10.1007/s00266-026-06155-w
Pharmacogenomics of antipsychotic-induced weight gain: A systematic review
Kronenbuerger, M., Yoshida, K., Li, P. Y., Tavakoli, E., Magarbeh, L., Elsheikh, S. S. M., Gorbovskaya, I., Zai, C. C. H., Fleischmann, R., Zai, G. C., et al. (2026) · Schizophrenia Research · doi:10.1016/j.schres.2026.07.013
Elkoshi, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1864104 · Cited by 1
Abbas, N., Memon, A. A., Zulfiqar, R., Noon, A. Z., Shah, S. M. A., Panhwar, K., Sadia, Z., Khan, M. S., Akbar, M. B., Iftikhar, S., et al. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002234
Mills, A. M., & Noble, E. E. (2026) · Appetite · doi:10.1016/j.appet.2026.108729
Peripheral nerve complications from medications utilised for weight loss: a systematic review
O’Gorman, C., O’Gorman, M., & Warren, N. (2026) · Journal of Neurology · doi:10.1007/s00415-026-14048-w
GLP-1 prescribing for individuals with schizophrenia-spectrum disorders in a safety net hospital
Khan, S., Browne, J., Schwarz, A. G., Weinberg, J., Gouse, B. M., & Brown, H. E. (2026) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2026.08.002
Laffin, L. J., Schlaich, M. P., Hall, M. E., Xie, C. C., Rao, G. S., Rettiganti, M., Dennehy, E. B., & Linetzky, B. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101783
GLP-1 receptor agonists after liver transplant: Early reassurance, unanswered questions
Albhaisi, S. A. M., Spagnoli, J., & Sharma, P. (2026) · Liver Transplantation · doi:10.1097/lvt.0000000000000978
Optimizing the Postpartum Period to Support Lifelong Health for Women with Obesity
Hawley, N. L., Rossillo, M., Chundury, A., McElfish, P. A., Adrien, N., & Bengtson, A. M. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00748-x
Gómez-Maldonado, I., Rodríguez-Arana, A., Tamayo-Pinzón, A., Albornoz-Suárez, J. E., Lopez-Franco, M. J., Mejia-Manrique, J. A., Forero-Caycedo, J. J., Rojas-Rodríguez, L. C., Buitrago-Ricaurte, N., Gaviria-Carrillo, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167108
Corona, G., Sparano, C., Romeo, M., Sedigh, O., Bettocchi, C., Rastrelli, G., Vignozzi, L., & Maggi, M. (2026) · The World Journal of Men s Health · doi:10.5534/wjmh.260045
Ji, L., Gao, L., Li, B., Liu, M., Zhang, X., & Meng, C. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02859-2
Ashtary‐Larky, D. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00751-2
Żurawski, T., & Bartosiewicz, A. (2026) · Nutrients · doi:10.3390/nu18162718 · Cited by 1
Chen, D., Ma, B., Sun, H., Zhang, J., Gong, L., Wang, W., Liu, Z., Zha, H., Du, S., Chen, M., et al. (2026) · BMJ Medicine · doi:10.1136/bmjmed-2026-003026 · Cited by 1
Milluzzo, A., Oteri, V., Manuella, L., Pulvirenti, A., & Frittitta, L. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02189-x
Lalani, I., Nambayan, R., Carbonell, C., Ruan, Y., O'Sullivan, D. E., Stukalin, I., Hilsden, R. J., & Brenner, D. R. (2026) · Cancer Control · doi:10.1177/10732748261483767 · Cited by 1
GLP-1/GIP Uptake, Indication, and Access Pathways Among US Adults in the Understanding America StudyPreprint
Chaturvedi, R. R., Gračner, T., Pérez‐Arce, F., Suen, S., Jin, J., Orriens, B., Pacula, R. L., Ward, A. S., Haile, R., & Kapteyn, A. (2026) · medRxiv · doi:10.64898/2026.08.28.26361368
Taslim, N. A., Hendrawan, A. F., Alfaray, R. I., Rasyid, H., Sabrina, N., Mayulu, N., Hadinata, E., Tjandrawinata, R. R., Rejeki, P. S., Salamah, S., et al. (2026) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2026.100417
Bowers, C. J., Ruelos, V. C. B., Roy, J. C., & Weiss, W. M. (2026) · Journal of orthopaedic surgery · doi:10.1177/10225536261488188
Obesity: Epidemiology, Causes and Prevalence
Knapp, E. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40344-6.00117-4
Wu, K. A., Choudhury, A., Wu, J. A., Shenoy, D. A., Song, J., Mai, E., Dhanjani, S. A., Shatkin, M. S., Wellman, S. S., Seyler, T. M., et al. (2026) · The Knee · doi:10.1016/j.knee.2026.104639
Exploring BMI Classification Changes and Disparities Upon Incarceration in U.S. Federal Prisons
Velez-Valle, E., Smith, E., Nishan, B., Edwards, M., & Holliday, M. K. (2026) · Journal of Correctional Health Care · doi:10.1177/10783458261485713
Sociodemographic disparities in semaglutide and tirzepatide prescription for obesity treatment
Le, M. T., & Stokes, A. (2026) · Health Affairs Scholar · doi:10.1093/haschl/qxag255
Global barriers to GLP-1 receptor agonist treatment in women: access, safety, and equity
Meek, C. L., Anjana, R. M., Chandiwana, N. C., Chow, E. W. K., Franco, D. R., Halpern, B., Lamptey, R., Lingvay, I., Ma, R. C. W., Mohan, V., et al. (2026) · The Lancet Obstetrics Gynaecology & Women s Health · doi:10.1016/s3050-5038(26)00228-1
Ahmad, A. E., Yamani, N. T., Alaqaili, A. F., Aldawas, S. S., Alotaib, N. Q., & Eldawlatly, A. A. (2026) · Saudi Journal of Anaesthesia · doi:10.4103/sja.sja_177_26
Elbatreek, M. H., Li, Z., Yu, X., Gehred, N., Gromova, T., Chen, J., Huerta, M., Muraoka, N., Jensen, M. B., Kartha, V. K., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag732 · Cited by 4
Effects of liraglutide on thyroid function tests in euthyroid patients with obesity
Elma, Y., & Topaloğlu, O. (2026) · Gazzetta Medica Italiana Archivio per le Scienze Mediche · doi:10.23736/s0393-3660.25.06282-5
Look, M., Bays, H., le Roux, C. W., Xavier, N., Allen, S. E., Jouravskaya, I., Stefański, A., Dimitriadis, G. K., Behrend, B., Ye, W., et al. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100347
Metadata
- Authors
- Wong, H. J., Sim, B., Teo, Y. H., Teo, Y. N., Chan, M. Y., Yeo, L. L. L., Eng, P. C., Tan, B. Y. Q., Sattar, N., Dalakoti, M., & Sia, C.-H.
- Affiliations
- National University of Singapore (SG)
- National University Heart Centre Singapore (SG)
- National University Hospital (SG)
- University of Glasgow (GB)
- Corresponding author
- Sia, Ching-Hui
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2025-01-22
- Volume
- 48
- Issue
- 2
- Pages
- 292-300
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4406726472
- Semantic Scholar
- 78bb0c3810a832316cd3e039722f8764a2c24747
- Cited by
- 208
- References
- 38
- Citations by year
- 2026: 136 · 2025: 72
- FWCI
- 28.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis (Writing support)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity, overweight, weight loss, body mass index, waist circumference, diabetes mellitus, treatment effect modifiers, HbA1c, route of administration
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Female, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Body Mass Index, Randomized Controlled Trials as Topic, Overweight, Waist Circumference
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.